The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
But there are no efficacy data, and the mechanism has a mountain to climb.
CRB-601 and PF-06940434 fall by the wayside.
BPI-572270 enters clinical trials.
The company has ditched a trial of drebuxelimab plus ivonescimab.
